124 related articles for article (PubMed ID: 6777678)
1. [Long-term therapy of tumor patients. Secondary cardiomyopathies (author's transl)].
Bolte HD
MMW Munch Med Wochenschr; 1980 Sep; 122(36):1219-22. PubMed ID: 6777678
[TBL] [Abstract][Full Text] [Related]
2. [The risks of the antineoplastic chemotherapy and the treatment of complications caused by cytostatic agents (author's transl)].
Gürtler R
Arch Geschwulstforsch; 1980; 50(2):141-52. PubMed ID: 7436698
[TBL] [Abstract][Full Text] [Related]
3. [Congestive cardiomyopathy after doxorubicin (adriamycin)author's transl)].
Kaduk B; Seiler G
Dtsch Med Wochenschr; 1977 Dec; 102(49):1813-7. PubMed ID: 271071
[TBL] [Abstract][Full Text] [Related]
4. [Cardiomyopathy due to adriamycin: the possibility of its prevention. Monitoring by noninvasive technics].
Bianchi L; Bertocchi C; Felci U; Ferrario G; Giani P; Mariani L; Medolago G; Sarti E
Minerva Med; 1989 Mar; 80(3):215-26. PubMed ID: 2717043
[TBL] [Abstract][Full Text] [Related]
5. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel: new preparation. No first-line use in metastatic breast cancer.
Prescrire Int; 2001 Dec; 10(56):178-9. PubMed ID: 11824441
[TBL] [Abstract][Full Text] [Related]
7. [Neurotoxic side effects of cytostatic therapy (author's transl)].
Strian F; Maurach R
Fortschr Neurol Psychiatr; 1981 Apr; 49(4):152-63. PubMed ID: 7239402
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis of adriamycin myocardiopathy using echocardiography].
Harpf H; Lehnert M; Tschech G
Acta Med Austriaca Suppl; 1979; 6():341-3. PubMed ID: 299226
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive methods for detection of cardiomyopathy in the course of antineoplastic treatment.
Jurga L; Mrinák J; Ponist J; Sefara P; Berc A
Neoplasma; 1982; 29(3):341-50. PubMed ID: 7133229
[TBL] [Abstract][Full Text] [Related]
10. Adriamycin-induced myocardial toxicity: new solutions for an old problem?
Outomuro D; Grana DR; Azzato F; Milei J
Int J Cardiol; 2007 Apr; 117(1):6-15. PubMed ID: 16863672
[TBL] [Abstract][Full Text] [Related]
11. [The cardiotoxicity of anticancer agents].
Wakasugi S
Ryoikibetsu Shokogun Shirizu; 1996; (14):83-7. PubMed ID: 9047803
[No Abstract] [Full Text] [Related]
12. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
Holmes FA
Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
[TBL] [Abstract][Full Text] [Related]
14. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
Gershanovich ML; Moiceenko VM; Orlova RV
Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of advanced breast cancer with 2 successive chemotherapeutic schedules].
Pérez JE; Machiavelli M; Romero A; Leone BA; Rabinovich MG; Arévalo E
Medicina (B Aires); 1982; 42(6 Pt 1):587-95. PubMed ID: 6897849
[No Abstract] [Full Text] [Related]
16. [The problem of accidental paravenous application of cytostatics--case history (author's transl)].
Sommer H; Meinhold P
Zentralbl Gynakol; 1981; 103(21):1324-8. PubMed ID: 6798785
[TBL] [Abstract][Full Text] [Related]
17. [Local administration of adriamycin (ADM) for malignant pleural effusion and pericardiac effusion in breast cancer].
Saisho S; Saeki T; Takashima S; Aogi K; Ohsumi S
Gan To Kagaku Ryoho; 2003 Dec; 30(13):2063-8. PubMed ID: 14712766
[TBL] [Abstract][Full Text] [Related]
18. [Toxic myocardiopathies in pediatrics (author's transl)].
Fermont L; Zucker JM; Maynier M; Asselain B
Ann Pediatr (Paris); 1981 Mar; 28(5):355-8. PubMed ID: 7247228
[No Abstract] [Full Text] [Related]
19. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
20. [The use of Cardioxan as a cardioprotective agent during antitumor chemotherapy].
Lichinitser MR; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
Ter Arkh; 1994; 66(7):54-6. PubMed ID: 7985130
[No Abstract] [Full Text] [Related]
[Next] [New Search]
